Eisenhauer Eric L, Abu-Rustum Nadeem R, Sonoda Yukio, Levine Douglas A, Poynor Elizabeth A, Aghajanian Carol, Jarnagin William R, DeMatteo Ronald P, D'Angelica Michael I, Barakat Richard R, Chi Dennis S
Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, MRI-1026, New York, NY 10021, USA.
Gynecol Oncol. 2006 Dec;103(3):1083-90. doi: 10.1016/j.ygyno.2006.06.028. Epub 2006 Aug 4.
To determine the survival impact of adding extensive upper abdominal surgical cytoreduction to standard surgical techniques for advanced ovarian cancer.
The records of all patients with stages IIIC-IV epithelial ovarian cancer who underwent primary surgery at our institution from 1998 to 2003 were reviewed. The cohort was divided into 3 groups. Group 1 patients required extensive upper abdominal surgery, such as diaphragm peritonectomy/resection, resection of parenchymal liver or porta hepatis disease and/or splenectomy with or without distal pancreatectomy, to achieve optimal cytoreduction (residual disease<or=1 cm). Group 2 patients were optimally cytoreduced by standard surgical techniques, including hysterectomy, oophorectomy, omentectomy, and bowel resection. Group 3 patients were suboptimally cytoreduced. Primary outcome measures were response to primary chemotherapy, progression-free survival, and overall survival.
The cohort of 262 patients was divided as follows: Group 1, 57 patients; Group 2, 122 patients; and Group 3, 83 patients. The median follow-up was 36 months (range, 1-94 months). Frequency of clinical complete response in Groups 1, 2, and 3 was 82%, 78%, and 57%, respectively. The median progression-free survival for Groups 1, 2, and 3 was 24, 23, and 11 months, respectively. Progression-free survival for Groups 1 and 2 were equivalent (P=0.53) and were significantly longer than for Group 3 (P<0.001). The median overall survival was 84 and 38 months for Groups 2 and 3, respectively, and had not been reached for Group 1 by 68 months. Patients in Group 1 had equivalent overall survival to patients in Group 2 (P=0.74) and improved survival over patients in Group 3 (P<0.001). Prognostic factors significant on multivariate analysis included stage, optimal status, and ascites.
Patients requiring extensive upper abdominal procedures to achieve optimal cytoreduction demonstrated a similar initial response, progression-free survival, and overall survival to patients optimally cytoreduced by standard surgical techniques. The presence of bulky upper abdominal disease alone did not appear to indicate poor tumor biology. This initial maximal surgical effort was associated with improved survival in patients who would have otherwise been suboptimally cytoreduced.
确定在晚期卵巢癌的标准手术技术基础上增加广泛上腹部手术细胞减灭术对生存的影响。
回顾了1998年至2003年在本机构接受初次手术的所有IIIC-IV期上皮性卵巢癌患者的记录。该队列分为3组。第1组患者需要进行广泛的上腹部手术,如膈肌腹膜切除术/切除术、肝实质或肝门疾病切除术和/或脾切除术,可伴有或不伴有胰体尾切除术,以实现最佳细胞减灭(残留病灶≤1 cm)。第2组患者通过标准手术技术实现了最佳细胞减灭,包括子宫切除术、卵巢切除术、大网膜切除术和肠切除术。第3组患者细胞减灭效果欠佳。主要结局指标为对初次化疗的反应、无进展生存期和总生存期。
262例患者的队列分组如下:第1组57例;第2组122例;第3组83例。中位随访时间为36个月(范围1-94个月)。第1、2、3组的临床完全缓解率分别为82%、78%和57%。第1、2、3组的中位无进展生存期分别为24、23和11个月。第1组和第2组的无进展生存期相当(P = 0.53),且显著长于第3组(P < 0.001)。第2组和第3组的中位总生存期分别为84个月和38个月,第1组至68个月时仍未达到中位总生存期。第1组患者的总生存期与第2组患者相当(P = 0.74),且生存期优于第3组患者(P < 0.001)。多因素分析显示,显著的预后因素包括分期、最佳状态和腹水。
需要进行广泛上腹部手术以实现最佳细胞减灭的患者,其初始反应、无进展生存期和总生存期与通过标准手术技术实现最佳细胞减灭的患者相似。仅存在大量上腹部疾病似乎并不表明肿瘤生物学行为不良。这种初始的最大手术努力与原本细胞减灭效果欠佳的患者生存期改善相关。